Comparison of a Pure Plug-Based versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis: @TheLancet
🥸Plavix for secondary prevention may be superior to aspirin
😱 Summary
👇👇👇
🥸1️⃣ For decades, aspirin has been the default long-term therapy for preventing recurrent cardiovascular events in patients with established coronary artery disease. It has been embedded in clinical guidelines based largely on historical data.
🥸2️⃣ However, multiple randomized trials have recently compared clopidogrel directly with aspirin as a single-agent strategy. This 2025 meta-analysis provides the most comprehensive assessment to date by combining patient-level data.
Global Uptake of GLP-1 Receptor Agonists in Obese, Non-Diabetic Patients with Cardiovascular Disease: @ESC_Journals
🥸New publication from our @heartwiselab research group: @MichaelGNanna
😱Older adults use: 1.9% of semaglutide and 1.3% of tirzepatide - summary
👇👇👇
🥸1️⃣ GLP-1 receptor agonists (GLP-1RAs) were originally developed for diabetes and weight loss. SELECT expanded their role, showing semaglutide reduces cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.
🥸2️⃣ SELECT enrolled 17,604 adults ≥45 years with overweight or obesity (BMI ≥27) and prior MI, stroke, or PAD, but no diabetes. Semaglutide led to a 20% relative risk reduction in major adverse cardiovascular events.
Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias: @NEJM
🥸 The statement: "Keep K above 4 and Mg above 2" still holds: #ESCCongress2025
😱 Summary
👇👇👇
🥸1️⃣ The POTCAST trial tested if raising potassium to the high-normal range (4.5–5.0 mmol/L) reduces malignant arrhythmias, hospitalizations, or death in patients with cardiovascular disease and an implanted defibrillator.
🥸2️⃣ It was a randomized, multicenter trial in Denmark enrolling 1,200 patients with potassium ≤4.3 mmol/L and an implantable cardioverter-defibrillator for primary or secondary prevention.
Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: @NEJM #ESCCongress2025
🥸 Does REBOOT-CNIC agree with BETAMI-DANBLOCK?
👇👇👇
🥸1️⃣ The REBOOT trial evaluated beta-blockers after MI in patients with LVEF >40%. The trial tested whether routine beta-blockers reduce death, reinfarction, or heart failure hospitalization.
🥸2️⃣REBOOT enrolled 8,438 patients with recent MI and LVEF >40%, across 109 centers in Spain and Italy. All underwent coronary angiography and received modern secondary prevention therapy. The design was PROBE: randomized, open-label, blinded endpoint adjudication.
Beta-Blockers after Myocardial Infarction in Patients without Heart Failure: @NEJM @ESCCongress
🥸 Is evidence still in favor of beta blockers post AMI? #ESCCongress2025
😱Summary
👇👇👇
🥸 1️⃣ The BETAMI–DANBLOCK trial, a large, pragmatic randomized trial from Denmark and Norway, asked whether long-term beta-blockers reduce death or cardiovascular events in post-MI patients with preserved or mildly reduced LVEF but no heart failure.
🥸 2️⃣ 5,574 patients with recent MI and LVEF ≥40% were randomized 1:1 to beta-blocker therapy or no beta-blockers within 14 days of the event, with outcomes tracked using complete national registry data and blinded adjudication.
Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial: @ESC_Journals
🥸Aspirin for primary prevention for older pts = MACE!
👇👇👇👇
🥸1️⃣ ASPREE was a large randomized trial designed to evaluate whether daily low-dose aspirin prevents cardiovascular events in initially healthy older adults.
🥸2️⃣ ASPREE enrolled 19,114 community-dwelling adults ≥70 (≥65 for US minorities), free of prior cardiovascular disease, dementia, or disability. Participants were randomized to 100 mg aspirin or placebo and followed in-trial (median 4.7 yrs) and post-trial (median 4.3 yrs).